Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-118 plus Oxaliplatin vs S-1 plus Cisplatin in Advanced Gastric Cancer
NCT02322593Phase 3Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Dec 2014
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of S-1 + leucovorin in gastric cancer (GC) (2 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: Overall Survival at 38 months. Started Dec 2014; status: completed.
02
Drugs
S-1 + leucovorin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT02322593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02322593.